Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT

Core Points - A class action securities lawsuit has been filed against Altimmune, Inc. for alleged securities fraud affecting investors between August 10, 2023, and June 25, 2025 [1] - The lawsuit follows a significant decline in Altimmune's stock price after the announcement of disappointing results from the IMPACT Phase 2b MASH trial of Pemvidutide, where the primary endpoint of fibrosis reduction did not achieve statistical significance [2] - Investors who suffered losses during the relevant time frame have until October 6, 2025, to request to be appointed as lead plaintiff, with no out-of-pocket costs to participate in the class action [3] Company Details - On June 26, 2025, Altimmune reported that the IMPACT Phase 2b MASH trial did not meet the expected statistical significance for fibrosis reduction, leading to a 53.2% drop in stock price from $7.71 to $3.61 per share in one day [2] - The company attributed the disappointing results to the Phase 2 nature of the trial and expressed hope for better outcomes in the upcoming Phase 3 trial [2] Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4]